Is Bigger Always Better in Arterial Intervention?
|
|
- Griffin Dean
- 5 years ago
- Views:
Transcription
1 IAGS 1998 Proceedings Is Bigger Always Better in Arterial Intervention? Ted Feldman, MD S T R E S S 1 and BENESTENT 2 ushered in the era of stent use for the prevention of restenosis. These studies defined angiographic restenosis rates as one third lower for stents versus PTCA and target lesion revascularization rates in BENESTENT I I that were below 10%. Additional refinements in stent implantation techniques have further improved six month angiographic and clinical outcomes. After stent deployment, an intravascular ultrasound cross-sectional lumen area greater than 9 mm 2 has been associated with restenosis rates well under 10%. Discussion of restenosis rates in the single digit range are common. Acceptance of the bigger is better concept is uniform. 3 It is critical to note that these excellent results have been described in highly selected patient populations. STRESS and BENESTENT were carried out in patients with reference vessels with a mean diameter of 3.0 mm. The bigger is better concept predicts excellent results in these vessels and even better restenosis rates in larger vessels such as the iliac and carotid arteries. Despite the excellent study results, numerous clinical situations are more difficult to deal with and many problems remain unsolved. We can categorize the most problematic patient subgroups by simply reviewing the reasons for excluding patients from enrollment in recent stent trials. These reasons include smaller vessels with From the University of Chicago Hospital, Pritzker School of Medicine, Hans Hecht Hemodynamics Laboratory, Chicago, Illinois. Presented at the Fifth Biennial International Andreas Gruentzig Society Meeting, Punta del Este, Uruguay. Address reprint requests to: Ted Feldman, MD, University of Chicago Hospital, 5841 S. Maryland Avenue, MC 5076, Chicago, IL reference diameters less than 2.5 or 3.0 mm, long lesions, diffuse disease, highly angulated proximal segments that make stent delivery difficult, vein graft and post bypass disease, densely calcified stenoses, lesions requiring staged therapy, and those containing thrombus or filling defects. A variety of other issues remain as well. Stents have not yet resolved a large number of clinical problems. This is reflected by the fact that our patients do not always mirror the STRESS and BENESTENT populations. A number of studies have described our real world experience. Among patients examined at Beaumont Hospital, 75% of coronary patients treated with catheter therapy were not found to have STRESS type coronary artery disease. 4 The target lesion revascularization rate in this group was 21% compared to 7.5% found in the minority of patients with STRESS lesions. Similarly less good results for small vessels, long lesions, ostial disease, total occlusions, vein graft lesions, restenotic lesions and patients with poor ventricular function have been described. 5 Higher restenosis rates in patients with smaller vessels and longer lesions have been well categorized. It has been demonstrated that as lesion length increases and vessel size decreases, target lesion revascularization rates rise sharply. This is especially true in vessels less than 2.75 mm diameter with lesion lengths greater than 15 mm. 6 This experience is shown in Figure 1. The distribution of vessel sizes in the general PTCA population has rarely been characterized. Clinical trial study populations reflect selected groups. Therefore, the mean reference vessel sizes for these patients is an artifact of the study inclusion criteria. Figure 2 shows the distribution of vessel sizes in my own practice. As Vol. 10, No. 8, October
2 FELDMAN Figure 1. The relationship between the reference vessel diameter and lesion length is shown for vessels less than 10 mm in length versus those greater than 15 mm in length. As a reference vessel declines to less than 2.75 mm in diameter the target lesion revas - cularization rate begins to increase sharply as lesion length increases. 6 0 A > 4 Reference Diameter (mm) (N = 1422 lesions/1042 patients) seen in Figure 2A, the histogram of reference diameter demonstrates that the majority of vessels are less than 3 mm. When considering only those vessels between 2 3 mm in diameter, we find that vessels that are 2.8 to 3.0 mm are clearly stentable, between 2.6 and 2.7 mm are possibly stentable, and the large segment of vessels between 2.0 and 2.5 mm remain problematic. If the larger end of this small vessel spectrum is treated with stent therapy, the angiographic results are good but the long term clinical results are not as good as those seen in STRESS and BENESTENT. The remainder of these vessels in a mm diameter range have even worse outcomes. Real world lesions differ from STRESS and BEN- ESTENT lesions primarily in terms of reference vessel size and lesion length. Both of these variables have a large impact on restenosis rates. Figure 3 shows the restenosis rates predicted by the bigger is better model for vessels 2 3 mm in diameter. It is clear that even with 0% residual stenosis after an intervention, restenosis rates of 25 40% are the best that can be achieved. Lesion length further detracts from the durability of these results. Both reference vessel diameter and lesion length must be considered when evaluating the results of various other trials. Simply looking at the bottom line six month target lesion revascularization or restenosis rate in isolation does not tell the entire story. Figure 4 shows the wide variations in reference vessel size and lesion length in a number of recent studies. Figure 4 also shows the variation in the incidence of diabetes mellitus from study to study. Diabetes is one of the most powerful predictors of restenosis and is also more prevalent in studies with smaller vessel size. It has been suggested that the smaller vessels are less clinically important because they are primarily branch vessels such as diagonal and obtuse marginal arteries. B Figure 2. Distribution of vessel size in clinical practice. ( A ) T h e histogram demonstrates that the majority of arteries in an unselect - ed population of angioplasty patients is less than 3 mm in diame - ter. ( B ) The pie chart shows the distribution of vessels between 2 and 3 mm. While those at the larger end of this range are stentable or possibly stentable, vessels between 2.1 and 2.5 mm remain poorly suited for stenting with current approaches. Therefore, they are thought to have less impact on late death and myocardial infarction. An analysis of the distribution of vessels in the STRATAS Trial (mean reference diameter of < 2.5 mm) showed a preponderance of LAD vessels as the vessel size decreased. 7 Thus, our selection of patients brings important small vessels into the case mix. The results of stent therapy in the smaller vessels have been disappointing. The use of coronary devices in smaller vessels is limited. Device use in practice is shown in Figure 5. When the overall experience is examined, stents alone or in conjunction with other devices were used approximately 60% of the time in In vessels of less than 2.5 mm, stents were used in only 15% of cases. The preponderance of device use in the remainder of this group is split between rotational atherectomy and balloon angioplasty. This reflects 522 The Journal of Invasive Cardiology
3 Is Bigger Always Better in Arterial Intervention? Figure 3. The bigger is better principle is illustrated in this fig - ure. The arrows demonstrate that for vessels between 2 and 3 mm in diameter, the probability of restenosis even with 0% resid - ual stenosis after an intervention is between 25 and 35% at best. Reprinted with permission from Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21: both the limitations imposed by the vessels and many of the limitations of both the current and older stent designs. Directional atherectomy is severely constrained by the device size. Rotational atherectomy is the most practically applicable intervention in the smaller vessels. Debulking is attractive as an adjunct therapy in vessels less than 3 mm in size. The concept of facilitated angioplasty has also been clearly d e m o n s t r a t e d. 8 The amount of lumen expansion for a given balloon size and pressure is significantly more favorable after debulking. Larger lumens can be achieved with smaller balloon-to-artery ratios and lower pressures. Debulking may minimize some of the limitations of stenting in smaller vessels (Figure 6). 9 The removal of calcifications and atheroma bulk maximizes the potential for delivery and symmetric expansion of stents in these arteries. With new stent designs, stenting has become practical in vessels that are mm in diameter. A randomized trial comparing rotational atherectomy with PTCA prior to stenting has demonstrated a lower target lesion revascularization rate after debulking prior to stent implantation compared to simple predilation prior to stenting. 1 0 The potential for stent therapy to be beneficial in vessels smaller than 2.5 mm, even with prior debulking, remains to be d e m o n s t r a t e d. Good late outcomes after catheter intervention have been predicted by good acute results for over a decade. Grüntzig demonstrated that post-procedure pressure gradients less than 15 mmhg were associated with STRESS-like late restenosis results, while post-procedure gradients greater than 15 mmhg were Figure 4. Reference vessel diameter, incidence of diabetes, and lesion lengths in a variety of recent coronary intervention trials. The benchmark STRESS and BENESTENT patients have larger reference vessel diameter, lower incidence of diabetes, and shorter lesion lengths than in many other trials. The results of the trials must be critically examined in conjunction with the patient population treat - ed. Some trial results seem to have especially poor late outcomes when only target revascularization rates are considered, but in view of these other variables the results may be quite reasonable. Vol. 10, No. 8, October
4 FELDMAN 100% 80% 60% 40% 20% 0% Overall Vessels 2.5 n = 351 n = 103 associated with much higher late event rates. 1 1 M o r e recent reports using angiographic analysis have found similar outcomes. 12 Post-PTCA residual stenosis of less than 30% is associated with substantially better outcome than residual stenoses that are greater than 30%. Provisional stenting approaches in which good PTCA results are accepted when Doppler flow reserve or fractional flow reserve determined from pressure gradients are optimal have had similar succ e s s. 1 3 The principle of a good acute result leading to a good late outcome has thus been reaffirmed repeatedly since the early 1980 s. It is clear that for the time being, our best approach in smaller vessels is to achieve optimal acute results. This requires the combined use of all the technologies available today. Stenting alone is clearly not the answer and may be facilitated greatly by debulking. The real solution to late durability in these smaller vessels will require the further study of intracoronary brachytherapy and the development of successful pharmacologic strategies designed to reduce restenosis. Stent = Rota-Stent = Rota = PTCA = Figure 5. Device use in The overall pattern of device use included 60% stenting. For vessels less than 2.5 mm, stents were used in fewer than 20% of patients while rotational atherectomy and PTCA comprised the major methods for catheter revascularization. REFERENCES 1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331: Serruys PW, DeJaegere P, Kiemeneij F, et al. A comparison of Figure 6. The left hand panel shows a chronic total occlusion in a patient with history of inferior infarction 8 years ago. After rota - tional atherectomy, as seen in the middle panel, there is a small caliber vessel with diffuse disease. In the right hand panel, after angio - plasty and placement of multiple stents, a reconstructed artery is visible. The patient had a normal 9 month follow up stress examination. Note that the guiding catheter is a French and the caliber of the vessel, even after stent placement, is in the 2.5 mm range. Therapy for diffusely diseased vessels is not realistically possible without a multi-modality approach. 524 The Journal of Invasive Cardiology
5 Is Bigger Always Better in Arterial Intervention? balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331: Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting, and directional atherectomy. J Am Coll Cardiol 1993;21: Tilli FV, Alabedi D, Kim JW, et al. Real life stenting: A comparison of target vessel revascularization in benestent-stress lesions to non benestent-stress lesions.c i r c u l a t i o n 1996;94 (Suppl 1): Sawada Y, Nosaka H, Kimura T, Nobuyoshi M. Initial and six months outcome of Palmaz-Schatz stent implantation: Stress/benestent equivalent vs non-equivalent lesions. J Am Coll Cardiol ; 2 7 : A. 6. Mehran R, Hong MK, Laskey AJ, et al. Vessel size and lesion length influence late clinical outcomes after native coronary artery stent placement. C i r c u l a t i o n 1997;96(Suppl 1): Feldman T, Bass TA, Kuntz RE, et al. Influence of vessel caliber on rotational atherectomy results. J Am Coll Cardiol ; 2 9 : A. 8. Safian RD, Freed M, Reddy V, et al. Do excimer laser angioplasty and rotational atherectomy facilitate balloon angioplasty: Implications for lesion-specific coronary intervention. JAmCollCardiol ; 2 7 : Levin TN, Carroll JD, Feldman T. High speed rotational atherectomy for chronic total coronary occlusions. Cathet Cardiovasc D i a g n ; 3 0 ( S u p p l ) : Naizi KA, Patel AA, Nozha F, et al. A prospective randomized study of the effects of debulking on restenosis. C i r c u l a t i o n 1997;96(Suppl 1): Anderson HV, Roubin GS, Leimbruger PP, et al. Measurement of trans-stenotic pressure gradient during percutaneous transluminal coronary angioplasty.c i r c u l a t i o n ; 7 3 : Martinez CA, Froidcoaur M, Mathus F, et al. Quantitative angiographic results after coronary angioplasty can predict early and long-term outcome.c i r c u l a t i o n 1997;96(Suppl 1): Serruys PW, de Mario C, Piek J, et al. Prognostic value of intracoronary flow velocity and diameter stenosis in assessing the short and long term outcomes of coronary balloon angioplasty: The DEBATE study (Doppler Endpoints Balloon Angioplasty Trial in Europe).C i r c u l a t i o n ; 9 6 : PA N E L D I S C U S S I O N MODERATOR: Thank you very much Ted, that was excellent. We have Dr. Feldman s paper open for discussion. The first comment is by Mark Reisman. MARK REISMAN: I just want to compliment you on an excellent presentation it was extremely concise. I think the issue that Ted was able to highlight, which I think is critical, is first and foremost the fact that the world seems to be broken down into particular segments: those with vessels greater than 3 millimeters and less than 3 millimeters. Although the bigger is better theory does hold to the larger vessels, it clearly appears that you need room to accommodate the intimal hyperplasia that exists after making a vessel larger. It appears that accommodation doesn t exist, at least in the smaller vessels. I think that is very important. The second issue that Ted highlighted was the issue of whether or not debulking could be helpful in the smaller vessels. I know that Antonio Colombo is currently doing a trial looking at debulking with either directional or rotational atherectomy to provide that accommodation for intimal hyperplasia. However, it clearly appears that stenting has set the current paradigm for the bigger is better philosophy. It seems to be extremely durable. There appears to be a significant amount of room for improvement. With that I would like to open up for questions. ANTONIO COLOMBO: I think it is very important for the future that we start to divide the population of lesions in small vessels into two groups: number one, the vessels which are small because there is a lot of plaque reducing the angiographic lumen to a small size throughout a long segment creating the angiographic appearance of a small vessel; and number two, the true small vessels where the plaque is not very large as far as mass is concerned. For example, if you see a left anterior descending that is 2 millimeters in diameter in its proximal segment, the vessel is most likely 3 mm or larger with a large plaque burden. On the other hand, a diagonal which is 2.5 mm is likely to be the true size of the vessel. LUIS DE LA FUENTE: I think that sometimes it is very difficult to define the exact size of the coronary vessel. When you have a very severe coronary obstruction and a poor distal flow, when you give intracoronary nitroglycerin and/or when you do an angioplasty you find that the vessel is larger. I wonder now how many times we denied a bypass to an artery with a severe obstruction and very poor distal runoff because we considered that the distal bed was not adequate for a bypass. I would like to ask you, Dr. Feldman, how did you evaluate the small vessels? TED FELDMAN: All of the data that I showed define vessel size by quantitative coronary angiography. Reference vessel size in most trials is measured both before and after the intervention. Trial lesions are focal; therefore, they are not as complicated as real-life lesions. Nitroglycerin is given before the intervention and most of the reference vessel diameters do not change much. The real-life problem is vessels that change dramatically after they have opened. Some flow has been restored and the distal reference size increases a great deal. The only way to really define vessel size in those arteries is to use intravascular ultrasound. The cardiovascular surgeon uses a rigid probe to determine vess e l size and this has no real meaning. They blindly pass a 1.5 mm probe and it gets stuck in the first side branch or bend that the probe encounters. This vessel is then deemed to be too small to bypass. We might also Vol. 10, No. 8, October
6 FELDMAN teach our surgeons how to use intravascular ultrasound epicardially during their procedures. PATRICIA THORPE: I just want to add that for many years now, the incidence of diabetes in all of the peripheral studies has been about 32 35%. I think that it is curious in the series that you quoted that it was 15%. You indicated that you believe that the percentage is going up, but for many years in the peripheral vascular disease studies it has been stable at about 30 or 35%. I m not so sure what that means in this regard because we now know that diabetes affects medium size vessels more. Perhaps there is a correlation. TED FELDMAN: I think it is an artifact of the patient selection criteria in coronary trials. Peripheral disease is usually diffuse disease, but the coronary trials are typically heavily weighted to include patients who have focal lesions rather than diffuse lesions. PATRICIA THORPE: Actually, diabetic patients have very nice looking large arteries. They could almost look perfect it is the tibial disease in many instances that is worse. No one mentions sexual difference in these small vessels versus large vessels in the coronaries and the response to intervention. I don t know if you see a trend or if you separate your patients in female and male because there may be an overall trend in size and then the response is due to other things. TED FELDMAN: The STRATAS Trial, which involved predominately smaller vessels, had a gender analysis. Gender did not fall out as an important factor among patients treated with rotational atherectomy. KIRK GARRATT: A practical concern is what we should do now. I think most of us are sold on the idea that the only way to get the best durable results is to get an optimal initial result and do whatever we can to contain an intimal hyperplasia and/or contain the adverse remodeling effect. Until we have a little more experience with radiation therapies and so forth, it looks like we are left without a lot to offer in terms of intimal hyperplasia. That leaves us with the remodeling issue. As you undoubtedly know, the GRII small vessel registry showed equally grim results. I think the restenosis rate in that population was 58%. There has been a lot of discussion about errors in terms of sizing of the stent among the GRII investigators. However, it seems unlikely that this will explain those results since these were all small vessels. I think the medium size was about 2.3 millimeters and the stents are 2.5 and 3.0 millimeters. Therefore, it is unlikely that will explain the high restenosis rate. The question now is whether you see anything on the horizon with respect to new stent designs that might be of benefit. Specifically, I m referring to the self-expanding stents. These stents may have great potential. As you know, Rob Schwartz in our laboratory has tested the Radius in vessels as small as 2.5. In his experience with animals, the stent after placement does continue to expand. You do get intimal hyperplasia, but you also get a positive remodeling effect from continued outward progression of the stent that seems to preserve lumens at least a month or two in the animal group. TED FELDMAN: I think that there are a few things that are optimistic. One is looking at our own data on debulking of smaller vessels in terms of one year clinical outcome. You can achieve good clinical outcomes without stents in vessels that are well developed. We looked at about 200 rotational atherectomy patients from 1994 before we were using elective stents in any significant numbers. At the end of one year, we had a clinical event rate of 20% in a population with a mean reference vessel size of 2.5 mm. This clinical outcome compares exactly with STRESS or BENESTENT or any of the focal lesion/large vessel trials. Using debulking aggressively is still the best approach to smaller vessels available at the moment. We will have to wait for results from debulking/stent trials such as the trial that Antonio Colombo is looking at. The self-expanding stent concept is very attractive and not yet another avenue. I think it is potentially important to have an appreciation for the late outcome of intimal hyperplasia. Retraction of the intimal hyperplasia tissue occurs in stents. Both Kimura and Pinkerton have demonstrated using different stents that one year MLDs are bigger than six months MLDs. We have seen that scars retract late and that a selfexpanding stent that will apply force to the vessel opposing the scar in the early phase may give you some of the tiny additional fraction of scar retraction. That is what Mark Reisman was talking about in his comment about accommodating this intimal hyperplasia. I think that this is a dynamic process. It will be very exciting if we could get negative remodeling until the scar begins to retract. We can rely on the behavior of the scar to help give us a late favorable o u t c o m e. SOUHEIL SADDEKNI: For stents, bigger is better. When the arteries are larger than 5 6 mm, developing intimal hyperplasia (1 2 mm) is less likely to cause significant restenosis. I reported on the significance of achieving good cosmetic results back in Bigger balloons and over-dilating was our means to do it then. Stents can achieve results now 526 The Journal of Invasive Cardiology
7 Is Bigger Always Better in Arterial Intervention? without overdilating. Other techniques, such as debulking and atherectomy, may be more appropriate in peripheral small arteries. R I C H A R D MYLER: Bigger is apparently better with most stents due to better apposition of the struts against the arterial wall which may present a more optimal radial force (hoop strength) versus the constrictive forces of adventitial constriction (remodeling) associated with restenosis. A controversy remains regarding bigger is better regarding atherectomy (or ablative) techniques. Some believe that the greater the initial gain, the more the net gain after one subtracts the late loss. However, many other investigators have noted that if one involves the media (or adventitia) to obtain a greater initial gain, then the late loss will usually exceed the initial gain and therefore result in a lower gain, i. e., restenosis. Furthermore, atherectomy devices may leave a sizable regional plaque (> 50%). Locally, an atherectomy catheter should perform optimal atherectomy removing as much plaque as possible or feasible without deep artery wall invasion. In this regard, IVUSguidance may be excellent. As Patrick Serruys has said, Mother Nature pays you back, i.e., the greater the injury, the greater the response. MARK REISMAN: I would just comment that I think the biggest challenge we have is to define what the arterial threshold is at which the artery starts responding in a very aggressive way. I think that is the challenge in both small and large vessels because we do see modest restenosis, and if we can somehow define that threshold I think we potentially optimize our results even further. ANTONIO COLOMBO: I believe we still do not have a modern debulking device. We know that by placing a stent we can get away in most cases even by leaving a large amount of plaque behind. This approach is not always rewarding; we are penalized with sub-optimal follow up in 32 40% of the lesions. If we had a more friendly and contemporary debulking device, our approach would be different. I think we need the industry to focus on new developments in technology in order to give us a contemporary debulking device. TED FELDMAN: I want to differ a little bit with you and Antonio Colombo. I think that if you look at the kind of tools we have used throughout civilization, it is not so much the tools as the way that they are used. I agree that we want to see the tools improve, but I think we have to figure out how to use them correctly to achieve optimal results. Vol. 10, No. 8, October
8
Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationWhy have interventional cardiologists salaries
The New 2013 Coronary Intervention Codes As of January 1, 2013, coronary intervention codes in use since 1992 were replaced by new codes with new values for complex interventions. By James C. Blankenship,
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
More informationExcimer Laser for Coronary Intervention: Case Study RADIAL APPROACH: CORONARY LASER ATHERECTOMY FOR CTO OF THE LAD FOLLOWED BY PTCA NO STENTING
Excimer Laser for Coronary Intervention: Case Study RADIAL APPROACH: CORONARY LASER ATHERECTOMY FOR CTO OF THE LAD FOLLOWED BY PTCA NO STENTING 1 2013 Spectranetics. All Rights Reserved. Approved for External
More informationCPT Code Details
CPT Code 93572 Details Code Descriptor Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationAdjunctive Stent Implantation Following Directional Coronary Atherectomy in Patients With Coronary Artery Disease
JACC Vol. 32, No. 7 December 1998:1855 60 1855 Adjunctive Stent Implantation Following Directional Coronary Atherectomy in Patients With Coronary Artery Disease EZIO BRAMUCCI, MD,* LUIGI ANGOLI, MD,* PIERA
More informationPlaque Removal Prior to Stent Implantation in Native Coronary Arteries: Why? When? and How?
IAGS 1998 Proceedings Plaque Removal Prior to Stent Implantation in Native Coronary Arteries: Why? When? and How? Issam Moussa, MD, Carlo Di Mario, PhD, MD, Antonio Colombo, MD From the Centro Cuore Columbus,
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationJournal of the American College of Cardiology Vol. 34, No. 4, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 4, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00324-1 Final
More informationJournal of the American College of Cardiology Vol. 39, No. 8, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01774-6
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationIVUS Analysis. Myeong-Ki. Hong, MD, PhD. Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea
IVUS Analysis Myeong-Ki Hong, MD, PhD Cardiac Center, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Intimal disease (plaque) is dense and will appear white Media is made of
More informationThe Use of Intravascular Ultrasound and Spot Stenting for the Treatment of Long Lesions and Small Vessels
IAGS 1998 Proceedings The Use of Intravascular Ultrasound and Spot Stenting for the Treatment of Long Lesions and Small Vessels Issam Moussa, MD, Joseph De Gregorio, MD, Carlo Di Mario, PhD, MD, Antonio
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationA Synergistic Approach to Optimal Stenting Directional Coronary Atherectomy Prior to Coronary Artery Stent Implantation the AtheroLink Registry
Journal of the American College of Cardiology Vol. 36, No. 6, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00967-0 A Synergistic
More informationJournal of the American College of Cardiology Vol. 34, No. 1, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 34, No. 1, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00151-5 Mechanisms
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationSmall Stent Size and Intimal Hyperplasia Contribute to Restenosis: A Volumetric Intravascular Ultrasound Analysis
720 JACC Vol. 26, No. 3 Small Stent Size and Intimal Hyperplasia Contribute to Restenosis: A Volumetric Intravascular Ultrasound Analysis GASTON R. DUSSAILLANT, MD, GARY S. MINTZ, MD, FACC, AUGUSTO KENNETH
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationIntracoronary Serum Smooth Muscle Myosin Heavy Chain Levels Following PTCA may Predict Restenosis
Clinical Studies Intracoronary Serum Smooth Muscle Myosin Heavy Chain Levels Following PTCA may Predict Restenosis Yasuhiro TSUCHIO,MD,ShigetoNAITO, MD, Akihiko NOGAMI,MD, Hiroshi HOSHIZAKI, MD, ShigeruOSHIMA,
More informationAre We Making Progress With Percutaneous Saphenous Vein Graft Treatment? A Comparison of 1990 to 1994 and 1995 to 1998 Results
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01324-9 Are We
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationSafety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997
Original Article Safety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997 Luiz Alberto Mattos, Ibraim Pinto, Alexandre Abizaid,
More informationIntravascular Ultrasound for Complex Cases
Intravascular Ultrasound for Complex Cases The Practical Value of IVUS Shigeru Nakamura M.D. Intravascular ultrasound imaging provides short axis information about the vessel. Image quality is not as clear
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationPCI for Ostial Lesion
PCI for Ostial Lesion ii) LAD ostial Osamu Katoh,M.D. kyoto Katsura Hospital Cardiovascular Center PCI for a LAD ostial lesion is well-known to be associated with a high restenosis rate because of excessive
More informationCalcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease
Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease Thomas M. Shimshak, MD Heart and Vascular Center Florida Hospital Heartland Medical Center
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationEndovascular beta-irradiation with a liquid 188 Re-filled balloon to reduce restenosis after coronary angioplasty.
Endovascular beta-irradiation with a liquid 188 Re-filled balloon to reduce restenosis after coronary angioplasty. Peix A., Llerena L., Ponce F., López A., López L., Guerrero I., Cabrera L.O., Maltas A.M.,
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationCoronary artery disease (CAD) is the REVIEW PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS
PROJECTED HEALTH AND ECONOMIC BENEFITS OF THE USE OF SIROLIMUS-ELUTING CORONARY STENTS Rodolphe Ruffy, MD, FACC,* and Raymond J. Kaden, MBA, CPA ABSTRACT Despite remarkable technological progress in interventional
More information2017 Cardiology Survival Guide
2017 Cardiology Survival Guide Chapter 4: Cardiac Catheterization/Percutaneous Coronary Intervention A cardiac catheterization involves a physician inserting a thin plastic tube (catheter) into an artery
More informationFractional Flow Reserve. A physiological approach to guide complex interventions
Fractional Flow Reserve A physiological approach to guide complex interventions What is FFR? Fractional Flow Reserve (FFR) is a lesion specific, physiological index determining the hemodynamic severity
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationOne-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial
Tabriz University of Medical Sciences Original Article One-year Outcome of Stenting for Long Coronary Lesions, a Prospective Clinical Trial Samad Ghaffari MD, Mohammad Reza Hasanian MD, Leili Pourafkari
More informationJournal of the American College of Cardiology Vol. 38, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01458-9 Cutting
More informationStent Trials in Acute Myocardial Infarction
IAGS 1998 Proceedings Stent Trials in Acute Myocardial Infarction Alfredo Rodríguez MD, PhD Primary angioplasty in the early phase of acute myocardial infarction has been demonstrated to reduce in-hospital
More informationIntracoronary Brachytherapy
Page 1 of 19 Search Search Health Technology Advisory Committee Home Publications Links Search Intracoronary Brachytherapy June 2001 Executive Summary Percutaneous transluminal coronary angioplasty (PTCA)
More informationSolving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System
Volume 1, Issue 1 Case Report Solving the Dilemma of Ostial Stenting: A Case Series Illustrating the Flash Ostial System Robert F. Riley * and Bill Lombardi University of Washington Medical Center, Division
More informationΚλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE
Κλινική Χρήση IVUS και OCT PERIKLIS A. DAVLOUROS ASSOCIATE PROFESSOR OF CARDIOLOGY INVASIVE CARDIOLOGY & CONGENITAL HEART DISEASE Conflict of interest None to declare While IVUS is the most used intravascular
More informationRadiation Safety Abbott Vascular. All rights reserved.
Radiation Safety More and more complex cases are performed Complexity Index and Fluoroscopy Time 2 3 Collimators / Distances The intensity of scattered radiation is a function of exposed field size Use
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationEvaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013
Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013 Disclosures Consultant- St Jude Medical Boston Scientific Speaker- Volcano Corporation Heart
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationCTO Re vascularization in 2013
CTO Re vascularization in 2013 Is it safe to use/stent the sub intimal space? Dimitri Karmpaliotis, MD, FACC, FSCAI Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia Dimitri.karmpaliotis@piedmont.org
More informationFLEXIBLE, BALOON EXPANDABLE
EARLY RESULTS OF A CLINICAL TRIAL OF FLEXIBLE, BALOON EXPANDABLE COVERED STENT GRAFT IN ILIAC OCCLUSIVE DISEASE Chris LeCroy Coastal Vascular and Interventional Pensacola, Florida Clinical Trial WL GORE
More informationThere are multiple endovascular options for treatment
Peripheral Rotablator Atherectomy: The Below-the-Knee Approach to Address Calcium Head On Peripheral Rotablator s front-cutting, diamond-tipped burr provides stable rotation in calcified lesions. BY SONYA
More informationThe New England Journal of Medicine INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS
INTRAVASCULAR GAMMA RADIATION FOR IN-STENT RESTENOSIS IN SAPHENOUS-VEIN BYPASS GRAFTS RON WAKSMAN, M.D., ANDREW E. AJANI, M.D., R. LARRY WHITE, M.D., ROSANNA C. CHAN, M.D., LOWELL F. SATLER, M.D., KENNETH
More informationCoronary artery stenting in unstable angina pectoris: a comparison with stable angina pectoris
Heart 1999;81:393 397 393 Coronary artery stenting in unstable angina pectoris: a comparison with stable angina pectoris P B M Clarkson, M Halim, K K Ray, S Doshi, M Been, H Singh, M F Shiu Department
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationIntravascular Ultrasound
May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient
More informationDo stents deserve the bad press? Mark A. Tulli MD, FACC
Do stents deserve the bad press? Mark A. Tulli MD, FACC Disclosures: None Introduction Stents don t help people. Stents are bad for patients. Heart Treatment Overused WSJ Study Finds Doctors Often Too
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More information2017 Cardiology Survival Guide
2017 Cardiology Survival Guide Chapter 2: Angioplasty/Atherectomy/Stent The term angioplasty literally means "blood vessel repair." During an angioplasty procedure, the physician inserts a catheter, with
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationCurrent PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era
3 Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era Pascalle S. Monraats, Willem R.P. Agema, Aeilko H. Zwinderman, Robbert J. de Winter, René
More informationEvolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationHaemodynamic Department, Evangelismos Hospital, Athens, Greece
Hellenic J Cardiol 47: 46-50, 2006 Case Report Unexpected Opening of a Totally Occluded Septal Branch Originating From an Atheromatous Lesion Successfully Treated with Angioplasty and Stenting ILIAS K.
More informationTurbo-Power. Laser atherectomy catheter. The standard. for ISR
Turbo-Power Laser atherectomy catheter The standard for ISR Vaporize the ISR challenge In-stent restenosis (ISR) Chance of recurring 7 115,000 + /year (U.S.) 1-6 Repeated narrowing of the arteries after
More informationRadRx Your Prescription for Accurate Coding & Reimbursement Copyright All Rights Reserved.
Interventional Radiology Coding Case Studies Prepared by Stacie L. Buck, RHIA, CCS-P, RCC, CIRCC, AAPC Fellow President & Senior Consultant Week of November 19, 2018 Abdominal Aortogram, Bilateral Runoff
More informationDespite its benefit over balloon angioplasty in patients
Coronary Heart Disease Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Jeffrey J. Popma, MD; Martin B. Leon, MD; Jeffrey W. Moses,
More informationPredictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease
Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,
More informationPeripheral and Cardiology Coder 2018
Peripheral and Cardiology Coder 2018 Cardiovascular Services and Procedures Prepared and Published By: MedLearn Publishing A Division of MedLearn Media, Inc. 445 Minnesota Street, Suite 514 St. Paul, MN
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationTotal occlusion at ostial Left internal mammary graft with successful angioplasty and longterm patency result
DOI 10.7603/s40602-014-0017-x ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 116 121 (2014) ISSN: 2315-4551 Case Report Total occlusion at ostial Left internal mammary graft with
More informationLesions at coronary bifurcations represent a challenging
Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Antonio Colombo, MD; Jeffrey W. Moses, MD; Marie Claude Morice, MD; Josef Ludwig, MD; David R. Holmes, Jr,
More informationIntracoronary stents reduce restenosis compared with balloon
Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy Comparative Mechanisms and Results Roxana Mehran, MD; George Dangas, MD, PhD; Gary S. Mintz, MD; Ron
More informationPCI for Bifurcation Coronary Lesion
PCI for Bifurcation Coronary Lesion Bifurcation Lesions PCI is Challenging Higher acute complication Lower success rates Higher restenosis & TLR Restenosis Rate 21 ~ 57% TLR 8 ~ 43% Event Free Survival
More informationSAFETY AND EFFICACY OF PTCA IN THE TREATMENT OF CORONARY TOTAL OCCLUSION
PAKISTAN HEART JOURNAL VOL. 34 No. 1-4 JAN-DEC 2001 SAFETY AND EFFICACY OF PTCA IN THE TREATMENT OF CORONARY TOTAL OCCLUSION SUMMARY AFSAR RAZA* Background: In recent years several centers have published
More informationJournal of the American College of Cardiology Vol. 36, No. 2, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 2, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00752-X A Comparison
More informationJournal of the American College of Cardiology Vol. 35, No. 2, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 2, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00567-7 Greater
More informationFFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
More informationDavide Capodanno, MD, PhD Associate Professor, University of Catania, Italy
Restenosis - Capodanno CardioLucca, November 28, 2014 Slide 1 Autumn in Lucca V Simposio - 28 Novembre 2014 4.30PM-4.45PM L incubo del paziente e le incognite del cardiologo: la restenosi intrastent resta
More informationMaking the difference with Live Image Guidance
Interventional Cardiology AlluraClarity Making the difference with Live Image Guidance Diagnosis and treatment of coronary artery diseases and atherosclerosis Where/who The First Bethune Hospital of Jilin
More informationCatheter Interventions for Kawasaki Disease: Current Concepts and Future Directions
REVIEW DOI 10.4070/kcj.2011.41.2.53 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Catheter Interventions for Kawasaki Disease: Current Concepts
More informationOptimal Coronary Balloon Angioplasty With Provisional Stenting Versus Primary Stent (OCBAS)
1351 Optimal Coronary Balloon Angioplasty With Provisional Stenting Versus Primary Stent (OCBAS) Immediate and Long-Term Follow-up Results ALFREDO RODRÍGUEZ, MD, PHD, FACC,* FRANCISCO AYALA, MD,* VICTOR
More informationUtility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography
Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography Jon C. George, MD; Vincent Varghese, DO From the Deborah Heart and Lung Center, Browns Mills, New Jersey. ABSTRACT:
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationDISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
More information866 JACC gol. 25, No. 4 March 15, 1995:866-70
866 JACC gol. 25, No. 4 Stent Implantation of Saphenous Vein Graft Aorto-Ostial Lesions in Patients With Unstable Ischemic Syndromes: Immediate Angiographic Results and Long-Term Clinical Outcome ELDAD
More informationInnovation by design. Technology that sets a new standard
Innovation by design Technology that sets a new standard Flexible nitinol scoring element with three rectangular spiral struts works in tandem with a semi-compliant balloon to score the target lesion Balloon
More informationIncidence and predictors of drug-eluting stent fractures in long coronary disease
International Journal of Cardiology 133 (2009) 354 358 www.elsevier.com/locate/ijcard Incidence and predictors of drug-eluting stent fractures in long coronary disease Hyun-Sook Kim a, Young-Hak Kim b,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of percutaneous laser coronary angioplasty Treating blocked coronary arteries
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationWhat Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas
What Coronary Specialists Teach The Vascular Community About Vessel Prep? Tony Das, MD Texas Health, Dallas Dallas, Texas Stent Era Lessons on Vessel Preparation Under expanded stent consequences Abrupt
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationFRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!!
FRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!! Juan Antonio Pastor-Cervantes,M.D FSCAI, FACC Cardiovascular Institute Memorial Regional Hospital Hollywood Florida
More information